logo-loader
viewReNeuron Group PLC

ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating Huntington's disease

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott following the release of new positive data relating to its CTX cell therapy candidate which has been published in the peer-reviewed scientific journal Stem Cells.

He says the new data shows for the first time that ReNeuron's CTX human neural stem cell line can 'rescue deficits' associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

Quick facts: ReNeuron Group PLC

Price: 138.5 GBX

LSE:RENE
Market: LSE
Market Cap: £44.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 posts early losses sparked by rising US coronavirus...

Headlines from the Proactive UK newsroom. FTSE100 posted early losses sparked by rising US coronavirus infections and China’s trade row with the US. The blue-chip index shed 10 points to 6,112. Royal Mail PLC (LON:RMG) is to axe 2,000 jobs or more than 20% of its managerial staff as part...

2 weeks ago

2 min read